COMMUNIQUÉS West-GlobeNewswire

-
Shire submits investigational New Drug Application to FDA for Gene Therapy candidate SHP654 for treatment of Hemophilia A
06/07/2017 - 13:00 -
Targovax ASA: Registration of share capital increase following the private placement
06/07/2017 - 11:06 -
Novartis receives approval in the EU for Cosentyx label update, includes long term superiority data versus Stelara in psoriasis
06/07/2017 - 08:51 -
Shire plc : Additional Listing
06/07/2017 - 08:00 -
MITHRA STRENGTHENS E4 PATENT POSITION IN AUSTRALIAN MARKET
06/07/2017 - 07:30 -
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
06/07/2017 - 07:00 -
MDxHealth Launches AssureMDx for Bladder Cancer Liquid Biopsy Test
06/07/2017 - 07:00 -
MDxHealth lance AssureMDx, un test de biopsie liquide pour la détection du cancer de la vessie
06/07/2017 - 07:00 -
Le candidat-médicament QRX-411 de ProQR pour le syndrome d'Usher obtient la désignation d'Orphan Drug (médicament orphelin) de la FDA et de l'EMA
06/07/2017 - 00:44 -
Taconic Biosciences and Pharmatest Services Ltd. Create First Human Immune System Model for Bone Metastasis
05/07/2017 - 23:26 -
ETC's Sterilization Systems Group Awarded Eight Contracts
05/07/2017 - 23:00 -
Bilan semestriel du contrat de liquidité DBV Technologies contractés avec Natixis
05/07/2017 - 22:30 -
Half-Year Report on the DBV Technologies Liquidity Contract with Natixis
05/07/2017 - 22:30 -
Minerva Neurosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
05/07/2017 - 22:05 -
Prothena Announces Initiation of Phase 2 PASADENA Study of PRX002/RG7935 in Patients with Early Parkinson's Disease
05/07/2017 - 22:05 -
Arques Clinic : FAB Generation: Fabulous at Fifty and Beyond
05/07/2017 - 19:13 -
Nature Publication Reports Favorable Clinical Trial Results of BioNTech's Individualized Cancer Vaccine IVAC® MUTANOME
05/07/2017 - 19:04 -
Essilor : Nombre total de droits de vote et d'actions composant le capital social au 30 juin 2017
05/07/2017 - 18:00 -
Essilor: Disclosure of Share Capital and Voting Rights Outstanding as of June 30, 2017
05/07/2017 - 18:00
Pages